<DOC>
	<DOCNO>NCT00114764</DOCNO>
	<brief_summary>The purpose study determine single dose pegfilgrastim able reduce time severe neutropenia patient receive induction consolidation myelosuppressive chemotherapy de novo acute myeloid leukemia similar filgrastim .</brief_summary>
	<brief_title>Trial Comparing Pegfilgrastim With Filgrastim Adjunct Chemotherapy Acute Myeloid Leukaemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Inclusion Histologically confirm de novo AML evidence absence antecedent hematologic disease &gt; 1 month duration , prior chemotherapy , prior radiation therapy myelodysplastic cytogenetics ( per exclusion criterion ) Life expectancy , treatment , &gt; 3 month Age &gt; 18 year ECOG performance status 0 , 1 2 Adequate organ function receive protocol specify chemotherapy Exclusion Subjects blast transformation chronic myeloid leukaemia ( CML ) Patients secondary AML ( Received previous chemotherapy radiotherapy ) Previous treatment AML Patients AML FAB type M3 ( Acute Promyelocytic Leukemia , APL ) M7 High risk ( Unfavourable ) cytogenetics [ ( 5/del ( 5q ) , 7/del ( 7q ) , ( 8 ; 21 ) del ( 9q ) complex karyotype , inv ( 3q ) , abn 11q23 , 20q , 21q , del ( 9q ) , ( 6 ; 9 ) , ( 9 ; 22 ) , abn 17p , complex karyotype ( &gt; 3 abnormality ) ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Acute myeloid leukaemia</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>NeulastaÂ®</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Consolidation</keyword>
</DOC>